Bottom line
LQIG vs XLV: the short answer
LQIG (State Street(R) SPDR(R) MarketAxess Investment Grade 400 Corporate Bond ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
LQIG is cheaper at 0.07% vs 0.08% — a difference of $1.00 a year per $10,000 invested.
Over one year, XLV returned +14.5% vs +1.8% for LQIG (reporting dates differ).
Updated Nov 19, 2026
LQIG vs XLV side by side
| LQIG | XLV | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | SPDR (State Street) |
| Category | Corporate Bond | Health Care Sector |
| Expense ratio | 0.07% | 0.08% |
| Annual cost per $10k | $7 | $8 |
| 10-yr cost on $10k (prospectus) | $113 | $103 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +1.8% | +14.5% |
| 5-yr return (annualized) | — | +8.1% |
| 10-yr return (annualized) | — | +9.8% |
| Best quarter | +9.1% | +14.5% |
| Worst quarter | −3.7% | −12.7% |
| Net assets (fund) | — | $40.6B |
| Number of holdings | — | 65 |
| Portfolio turnover | 62% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LQIG | XLV | Difference |
|---|---|---|---|
| 2024 | +1.8% | +2.5% | −0.7% |
| 2023 | +9.4% | +2.0% | +7.4% |
Source: Fund prospectus bar charts
Holdings overlap
LQIG and XLV share none of their top holdings.
LQIG top 10
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between LQIG and XLV?
Which is cheaper, LQIG or XLV?
Should I own both LQIG and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.